Growth inhibition of Friend erythroleukaemia cell tumours in vivo by a synthetic analogue of prostaglandin A: an action independent of natural killer-activity
1990

Prostaglandin A and Tumor Growth

Sample size: 120 publication Evidence: moderate

Author Information

Author(s): S. Marini, A.T. Palamara, E. Garaci, M.G. Santoro

Primary Institution: Department of Experimental Medicine and Biochemical Sciences, II University of Rome

Hypothesis

Can prostaglandin A treatment affect the tumorigenicity and proliferation of Friend erythroleukaemia cells in vivo?

Conclusion

The synthetic analogue of prostaglandin A significantly inhibited tumor growth and increased survival in mice.

Supporting Evidence

  • Daily treatment with the synthetic analogue of prostaglandin A delayed tumor appearance.
  • Treatment increased median survival time by 15-35%.
  • Prostaglandin A treatment did not significantly affect natural killer cell activity.

Takeaway

This study found that a special type of medicine called prostaglandin A can help slow down cancer growth and help mice live longer.

Methodology

Mice were treated with a synthetic analogue of prostaglandin A and tumor growth was measured over time.

Limitations

The study primarily focused on one type of cancer in mice, which may not directly translate to humans.

Participant Demographics

120 female DBA/2 mice, 6 weeks old.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication